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BACKGROUND: Current standards for assessment of tumour response to therapy (a) categorise therapeutic efficacy values,
inappropriate for patient-specific and deterministic studies, (b) neglect the natural growth characteristics of tumours, (c) are based on
tumour shrinkage, inappropriate for cytostatic therapies, and (d) do not accommodate integration of functional/biological means of
therapeutic efficacy assessed with, for example, positron emission tomography or magnetic resonance imaging, with data from
anatomical changes in tumour.
METHODS: A quantity for tumour response was formulated assuming that an effective treatment may decrease the cell proliferation
rate (cytostatic) and/or increase the cell loss rate (cytotoxic) of the tumour. Tumour response values were analysed for 11
non-Hodgkin’s lymphoma patients treated with
131I-labelled anti-B1 antibody and 12 prostate cancer patients treated with a
nutritional supplement.
RESULTS: Tumour response was found to be equal to the logarithm of the ratio of post-treatment tumour volume to the volume of
corresponding untreated tumour. Neglecting the natural growth characteristics of tumours results in underestimation of treatment
effectiveness based on currently used methods. The model also facilitates the integration of data from tumour volume changes, with
data from functional imaging.
CONCLUSION: Tumour response to therapy can be assessed with a continuous dimensionless quantity for both cytotoxic and cytostatic
treatments.
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Assessment of tumour response (TR) to therapy is necessary for
evaluation of the efficacy of novel anticancer drugs in clinical
trials. Furthermore, response evaluation with high individual
precision may facilitate individualised therapy rather than
standardised treatment regimen in daily clinical practice.
Tumour shrinkage has been traditionally used as a measure of
treatment efficacy. For example, the response evaluation criteria in
solid tumours (RECIST) is currently adopted by academic and
industrial groups (Miller et al, 1981; Therasse et al, 2000), where
response to therapy is categorised as follows: complete response
(CR), the disappearance of all target lesions; partial response (PR),
at least a 30% decrease in the sum of the longest diameter of all
target lesions; progressive disease (PD), at least a 20% increase in
the sum of the longest diameter of all target lesions or the
appearance of one or more new lesions; and stable disease (SD),
neither sufficient shrinkage to qualify for PR nor sufficient
increase to qualify for PD (Therasse et al, 2000; Eisenhauer et al,
2009). Appropriateness of RECIST criteria, for example, whether
the change in tumour size is a proper end point for response
assessment, has been widely discussed (Barnacle and McHugh,
2006; Tuma, 2006; Twombly, 2006; Eisenhauer, 2007). The specific
criteria have been developed for different types of cancers, for
example, prostate cancer (Scher et al, 2008) and malignant
lymphoma (Cheson et al, 2007). However, this study was focused
only on quantification of TR to therapy, regardless of the type of
tumour and clinical measures other than tumour response.
The following limitations can be identified in current standards
for quantification of TR to therapy:
(1) Traditional standards may not be appropriate to assess the
efficacy of emerging numbers of cytostatic agents, which do not result
in tumour regression to a point of PR or CR. Proposals of a general
means of assessment of both cytocidal and cystostatic effects must be
developed (Michaelis and Ratain, 2006; Gwyther and Schwartz, 2008).
(2) The natural growth rate of tumour is not considered. A
certain treatment that kills the same ratio of tumour cells in two
different tumour types will give different results if the natural
proliferation rates of tumour cells are different.
(3) Adopting the current standards will convert a continuous
variable, as TR, into a discrete variable, resulting in the loss of
information. This will make comparison of individual, or
combination of, treatments less accurate. Furthermore, attempts
to relate treatment efficacy to molecular or cellular characteristics
of tumours, for example, by systems biology approach, will be
rather difficult when data are categorised. Karrison et al (2007),
based on suggestions by Lavin (1981), demonstrated that clinical
trial designs that treat change in tumour size as a continuous
variable are feasible (Karrison et al, 2007). They used the logarithm
of the ratio of tumour volume after therapy to that at baseline as an
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send point for quantification of TR, denoted as LR (log ratio)
(Karrison et al, 2007).
(4) Many studies have shown that the effect of treatment on
tumours can be assessed by means of changes in tumour
characteristics other than size, for example, estimated by positron
emission tomography (PET) or magnetic resonance imaging or
spectroscopy (MRI/MRS) (Padhani and Miles, 2010). Available
standards do not accommodate mathematical integration of
physiological or functional imaging modalities into anatomical
changes in tumour and new methods must evolve (Jaffe, 2008).
The aim of this study was to develop a mathematically accurate
and biologically relevant method for assessment of TR to any type
of treatment.
MATERIALS AND METHODS
Kinetics of tumour growth
Volumetric growth rate of tumours can be quantified with specific
growth rate (SGR), described as relative volume change per time
unit. Quantification of growth rate with SGR is mathematically
more accurate and biologically more relevant than the widely used
parameter tumour volume doubling time (DT) (Mehrara et al,
2007, 2009). The SGR of a tumour during time period from t0 to t
can be calculated from tumour volumes at the start and at the end
of this period, V0 and V, respectively:
SGR ¼
lnðV=V0Þ
ðt   t0Þ
ð1Þ
More rapidly growing tumours have higher SGR values, SGR¼0
represents non-growing tumours, and negative SGR values can be
assigned to tumour regression. Specific growth rate is constant for
exponentially growing tumours; however, if SGR is time depen-
dent, as for non-exponentially growing tumours, the above
equation can be rewritten as follows:
ln
V
V0
  
¼
Z t
t0
SGRðtÞdt ð2Þ
where SGR(t) is the SGR at time t. The value of SGR(t) depends on
the level of cell proliferation rate, CPR(t), and cell loss rate, CLR(t),
at time t:
SGRðtÞ¼CPRðtÞ CLRðtÞð 3Þ
TR to therapy
If the natural growth of tumour is interrupted by therapy, an
effective therapeutic agent may increase the CLR (cytotoxic effect)
and/or decrease the CPR (cytostatic effect) of tumour. Specific
growth rate will then decrease to SGR0 regardless of the mechanism
of the therapeutic effect:
SGR0ðtÞ¼SGRðtÞ DSGRðtÞð 4Þ
where DSGR(t) is the effect of treatment at time t. Temporal
variation of SGR0 depends on all factors that naturally affect
tumour growth as well as the effect of therapy. Readjustment and
integration of the above equation over time gives:
Z t
ti
DSGRðtÞ dt ¼
Z t
ti
SGRðtÞ dt  
Z t
ti
SGR0ðtÞ dt
where ti and t are the time of therapy initiation and efficacy
assessment, respectively. The right side of the above equation can
be replaced using Equation (2), which gives:
Z t
ti
DSGRðtÞ dt ¼ ln
Vn
Vi
  
 ln
Vt
Vi
  
where Vi is tumour volume at the time of therapy initiation, and
Vt and Vn are the volume of treated and corresponding
(hypothetical) non-treated tumour at the time of efficacy assess-
ment, respectively. The left side of the above equation is the over-
all effect of treatment during time from treatment initiation to
time of efficacy assessment, and can be denoted as TR. Since
ln(Vn/Vi) ln(Vt/Vi)¼ ln(Vt/Vn):
TR ¼ ln
Vt
Vn
  
ð5Þ
TR is a general continuous dimensionless quantity for tumour
response to both cytotoxic and cytostatic therapeutic effects. TR
can thus be calculated by the logarithm of the ratio between the
post-treatment volume of tumour and the volume that the tumour
would have had (at the time of efficacy assessment) if the growth
was not influenced by therapy. The value of Vn cannot be defined,
but only estimated based on the natural growth model of tumour.
To estimate Vn the following assumptions were used (cf. Figure 1):
(1) tumour volume at first diagnostic investigation is Vd; (2) therapy
is initiated at a time point Dtpre after measurement of Vd;( 3 )t u m o u r
grows exponentially with a constant SGR(t)¼SGR0 during the
studied time period and tumour volume at the time of therapy
initiation is Vi; (4) tumour response is assessed at a time point Dtpost
after therapy initiation and tumour volume at the time of efficacy
assessment is Vt; and (5) tumour would continue to grow with SGR0
if the growth was not interrupted and its volume would be Vn at the
time of efficacy assessment.
Application to patient data
Tumour response values were calculated for treatment of non-
Hodgkin’s lymphoma patients with
131I-labelled anti-B1 antibody,
Treatment initiation
Vi
Vd
Vt
e2
Vn
Efficacy assessment
e1
LR
TR
Err
Time
tpre tpost
I
n
(
V
)
Figure 1 Definition of the parameters used in the study. Vd, Vi, and Vt are
tumour volumes at diagnosis, therapy initiation, and time of efficacy
assessment, respectively. Tumour volume would increase to Vn at the time
of efficacy assessment if therapy was not started. TR¼tumour response
value derived in this study, LR¼log ratio measure for quantification of
treatment effectiveness, e1 and e2¼underestimation of TR if pretreatment
or post-treatment growth of tumour is neglected, respectively. Err¼overall
underestimation of TR if pretreatment and post-treatment growth of
tumour are neglected (TR¼LRþe1þe2).
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swhere data were retrieved from a previously published article
(Sgouros et al, 2003). The study was selected based on the
availability of tumour volumes and the time of pretreatment and
post-treatment volume estimations in each patient, information
necessary for TR calculation. Total tumour burden was assessed by
drawing contours around all lymphoma lesions identified on
whole-body CT or MRI. Two more patients are included in the
original article, where tumours disappeared after treatment. Those
data were excluded in this study. Average post-treatment
re-growth of tumour volumes used as an estimation of the natural
growth rate of non-Hodgkin’s lymphomas in this study.
Another set of data were retrieved from the literature, where
prostate-specific antigen (PSA) increase rates before and after
treatment with a nutritional supplement were available in 12
prostate cancer patients (Guess et al, 2003). Tumour response
values were calculated using PSA levels before and after treatment
for assessment of treatment efficacy.
Tumour response values were calculated for non-Hodgkin’s
lymphoma patients using total tumour burden as reference and
for prostate cancer patients using PSA level as reference,
respectively. On the basis of the calculated mean and standard
deviation of TR and LR in each group of patients, frequency
distribution of TR and LR were approximated with corresponding
normal distribution with the same mean and standard deviation
values in each group, respectively.
RESULTS
When the tumour response model developed in this study
(Equation (5)) is applied to an exponentially growing tumour,
TR is related to tumour volume and growth rate as follows
(Figure 1):
TR ¼ ln
Vt
Vd
  
|ﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄ}
LR
þSGR0   Dtpre |ﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄ}
e1
þSGR0   Dtpost |ﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
e2 |ﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ{zﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄﬄ}
Err
ð6Þ
The first term on the right-hand side of the above equation, LR, is
the treatment effectiveness where the natural growth of tumour is
neglected and is equivalent to the LR measure suggested by
Karrison et al (2007). LR values less than  0.5, between  0.5 and
þ1, and larger than þ1 correspond to progressive disease, stable
disease, and partial response according to RECIST, respectively.
The second term, e1, and the third term, e2, represent tumour
growth before and after treatment initiation, respectively. The
overall effect of tumour growth from the time of diagnosis to the
time of efficacy assessment, Dt, sums up as follows:
TR ¼ ln
Vt
Vd
  
þ SGR0   Dt ¼ LR þ Err ð7Þ
The above equation indicates that evaluation of treatment
effectiveness by comparing the volume of treated tumour with
pretreatment tumour volume underestimates the effect of therapy
by Err.
If a therapeutic drug has pure cytostatic effect, that is, the drug
inhibits tumour growth, but does not destroy existing tumour
cells, and if the drug can completely block tumour growth, the
tumour volume at the time of efficacy assessment will be the same
as the tumour volume at the time of treatment initiation, Vi. The
cytostatic efficacy of treatment is then e2¼ln(Vn/Vi) (Figure 1). If
the drug can partially control tumour growth, the tumour volume
at the time of efficacy assessment will be larger than Vi (closer to
Vn) and the treatment efficacy will be less than e2 in Figure 1. Note
that tumour volume at the time of efficacy assessment is, however,
larger than tumour volume at the time of diagnosis, Vd. According
to RECIST, a Vt of more than 1.73Vd (20% increase in diameter)
will be considered as progressive disease. For a tumour with DT
shorter than 27 days (SGR 42.6% per day) and a treatment that
completely blocks tumour growth, the drug will be considered
without any effect and be categorised as progressive disease
according to RECIST.
The frequency distributions of TR and LR are shown in Figures
2A and B for non-Hodgkin’s lymphoma and prostate cancer
patients, respectively. The results show that LR largely under-
estimates tumour response compared to TR.
DISCUSSION
Traditional quantification methods used in oncology can give
contradictory results to mathematically accurate and biologically
relevant methods (Mehrara et al, 2007, 2009). In this article, we
present a dimensionless continuous quantity for objective assess-
ment of TR, regardless of tumour type, clinical measures other
than tumour response, and the mechanism of the effect of therapy
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Figure 2 Frequency distributions of TR and LR based on treatment
results of (A) 11 non-Hodgkin’s lymphoma patients and (B) 12 prostate
cancer patients. The mean and standard deviation values were obtained for
each group and the corresponding normal distributions were drawn.
TR: mean¼4.16 and 0.35, s.d.¼1.69 and 0.06; LR: mean¼1.02 and 0.1,
s.d.¼1.03 and 0.02 for non-Hodgkin’s lymphoma and prostate cancer
patients, respectively. TR and LR values were calculated from changes in
tumour volume and PSA level in non-Hodgkin’s lymphoma and prostate
cancer patients, respectively.
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son tumour: cytotoxic and/or cytostatic. Studies have shown that
tumour growth rate is a valuable parameter for, for example,
prediction of recurrence after surgery (Cucchetti et al, 2005) and
survival of patients (Blankenberg et al, 1995), and the change in
tumour growth rate can serve as a surrogate end point for
determination of therapy response (Haney et al, 2001). In this
study, a simplified formula was derived based on the effect of
therapy on kinetics of tumour growth. Tumour response was
measured by the logarithm of the ratio of post-treatment tumour
volume to the volume of tumour (at the time of efficacy
assessment) if therapy was not initiated. TR¼0 indicates no
effect, and the larger TR value the more effective therapy. A
negative TR value indicates post-treatment tumour swelling or
growth enhancement.
TR values are larger than corresponding LR values, which were
used by Karrison et al (2007). The value of LR is calculated as the
logarithm of the ratio of post-treatment tumour volume to the
pretreatment tumour volume. The natural growth of tumour
during diagnosis and therapy initiation as well as after therapy is
neglected in the LR value. There might be a few weeks or longer
delay between tumour diagnosis and initiation of therapy due
to practical limitations or necessity of further evaluations.
Tumours continue to grow during this period. As an example,
the volume of a tumour with DT of 70 days will increase 23%
during 3 weeks. Repopulation of tumour cells during therapy, for
example, between cycles of chemotherapy, is also an important
factor that should not be neglected (Davis and Tannock, 2000;
Kim and Tannock, 2005). The overall underestimation of treatment
effectiveness by LR (Err) is larger when tumour is rapidly growing
or the time between pretreatment and post-treatment volume
assessments is long. The relative importance of Err also depends
on dose–response relation, that is, for a more effective drug LR is
less affected by this error.
The generally used methods when comparing the post-treatment
volume of tumour with the pretreatment volume will thus result in
underestimation of treatment effectiveness. It has already been
shown that RECIST underestimates the effect of imatinib on
metastatic gastrointestinal stromal tumour (Choi et al, 2007). The
fact that treatment effectiveness is underestimated by LR or
RECIST has important implications on assessing the efficacy of
new anticancer drugs or combinations of therapies.
It has been demonstrated that clinical trial designs based on LR
are feasible (Karrison et al, 2007), which suggests that TR can also
be used for such studies. The main difference between TR and LR
is the reference volume of tumour for efficacy assessment, which is
the volume of corresponding untreated tumour or pretreatment
volume of tumour for TR and LR, respectively. The statistical
aspects of using such continuous variables in clinical trials, for
example, handling extreme cases as complete disappearance of
lesions in two patients in this study, are discussed elsewhere
(Karrison et al, 2007). Here we discuss the advantages and
limitations of using TR as a quantity for tumour response.
The main limitation with using TR, compared to LR, is the
estimation of the volume of an untreated tumour at the time of TR
evaluation, which needs the natural growth model of tumour. In
this study, we assumed an exponential model for natural growth of
tumours. However, the presented formula for calculation of TR
(Equation (5)) can be used for any growth model, provided that
the non-exponential growth characteristics of tumour and Vn can
be estimated.
The natural growth rate of tumours can be estimated by
appropriate techniques according to the available data in each
study. Owing to lack of information, we estimated the growth rate
of untreated non-Hodgkin’s lymphoma tumours from the average
re-growth rate of tumours after therapy, which might be different
from the true growth rate of tumours before treatment. However,
these data were used only for demonstration, and no clinical
interpretation of the results should be made. If tumour volumes at
two occasions before start of therapy are available, for example,
having two CT scans at diagnostic investigation and an investiga-
tion just before therapy initiation, natural SGR of tumour and
consecutively Vn can be calculated using Equation (1). Taking both
inter- and intra-operator as well as inter-scan variability into
account, an increase of the measured volume by more than 25% is
needed for a 95% likelihood of being a true growth, rather than
measurement inaccuracy. For an exponentially growing tumour,
increase of the measured volume will be more than 25% if the
measurement time interval between two investigations is longer
than 0.32 DT.
If tumour volume before treatment is only available at one
occasion, for example, the first diagnostic imaging, tumour volume
at the time of therapy initiation can be estimated by back-
extrapolation of volume regression curve during therapy, which
might be described by exponential model (Stein et al, 2008). That
measure together with the first tumour volume available can be
used for estimation of the natural SGR of tumour.
However, we used PSA level as reference, instead of tumour
volume, for calculation of TR and LR in prostate cancer patients
and the results were similar to when tumour volume was used for
calculations in non-Hodgkin’s lymphoma patients. This indicates
that TR values calculated based on tumour marker level can be
used for quantification of treatment efficacy in some types of
tumours. Measurement of tumour marker level before the
initiation of treatment is usually more practical in clinical research
and practice. However, other factors that may affect tumour
marker level, for example, PSA decline due to dedifferentiation of
the tumour as it becomes anaplastic, must be considered, when
post-treatment changes of tumour marker level is studied.
Tumour structure can be rather non-homogeneous, consisting
of, for example, different clones of cancer cells (with different
sensitivities to an anticancer agent), stroma and necrotic areas.
The value of SGR of the tumour may then be obtained from the
spatial distribution of SGR within tumour, sgr(x,y,z):
SGR ¼
1
V
I
V
sgrðx; y; zÞ dx   dy   dz: ð8Þ
An effective treatment can reduce sgr(x,y,z) differently in different
parts of the tumour depending on, for example, pharmacokinetics
and dose–response of a systemically used agent. This will
accordingly cause a reduction in SGR of tumour as was used in
the presented model (Equation (4)). Studies have shown that
functional imaging variables might be correlated with tumour
growth rate, for example, using PET (Duhaylongsod et al, 1995;
Tann et al, 2008). Further developments in this field can facilitate
tumour SGR estimation by functional imaging before treatment as
well as integration of TR data based on anatomical changes in
tumour with other means of tumour response assessment by
functional imaging with MRI (Chenevert et al, 1997) or PET
(Stroobants et al, 2003; Boss et al, 2008).
In this study, we assumed that TR is evaluated at a specific
occasion after treatment, as it is usually done in clinical studies.
However, temporal changes of tumour SGR after treatment can
also give valuable information such as progression due to the
resistant clones of tumour, which can be identified with the point
that SGR starts rising. However, this remains to be studied.
Time to event, for example, time to progression (TTP) or
progression-free survival (PFS), is an end point that is also
recommended for assessment of therapeutic efficacy (Scher et al,
2008; Eisenhauer et al, 2009). An interesting aspect of the
presented method in this study is that Equations (1) and (5)
imply that TTP is linearly related to TR. It should be noted that in
this context, the TTP refers to the progression of the tumour(s)
under study, whereas from a clinical perspective, appearance of
new metastatic lesions may be considered as disease progression.
However, the metastases might have been settled before the start of
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streatment or the effect of treatment might be different on the
primary tumour and metastases.
In conclusion, a number of flaws can be identified in
quantification methods of TR used in available standards, for
example, neglecting the natural growth rate of tumour, which
leads to underestimation of treatment effectiveness. The logarithm
of the ratio of treated tumour volume (tumour marker level) to the
volume (tumour marker level) of corresponding non-treated
tumour is a general continuous quantity for tumour response
to both cytostatic and cytotoxic agents. It can also accom-
modate integration of data from anatomical changes of tumour
with data from changes in other biological characteristics of
tumour after therapy. These results are valuable for clinical
studies, revision of current standards for assessment of TR,
and also a deterministic approach for individualised therapy in
oncology.
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